ACT Biotech Inc is a San Francisco-based, privately held biopharmaceutical company focused on the development and commercialization of targeted cancer drugs.[1][2] It was founded in 2008.[3]

The Company's clinical stage pipeline includes:

  • Telatinib, an oral kinase inhibitor for the first-line treatment of advanced gastric cancer. It has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA).[4] It has reported encouraging interim results from a phase II trial.[1]
  • ACTB1003, an oral kinase inhibitor that targets cancer cells through multiple modes of action. It inhibits cancer cell growth by targeting the FGF receptor family, which are mutated in a number of human cancer types. ACTB1003 also directly induces apoptosis by targeting kinases downstream of the PI3K pathway, all at low nanomolar concentrations.

Other pipeline products include an oral Aurora A and B kinase inhibitor at the pre-IND stage, and an ABL tyrosine kinase inhibitor targeting the T315I mutant enzyme in pre-clinical development.[5][6]

References

  1. 1 2 "ACT BIOTECH Announces Positive Interim Phase 2 Results with Telatinib in First-line Gastric Cancer". 11 Oct 2010.
  2. ↑ "ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare". 7 May 2008. Archived from the original on 25 October 2016. Retrieved 23 January 2018.
  3. ↑ Leuty, Ron (February 19, 2013). "ACT Biotech co-founder Ali Fattaey makes tracks to Curis". San Francisco Business Times. Retrieved October 24, 2016.
  4. ↑ "ACT Biotech Receives Orphan Drug Designation for Telatinib, an Orally Available and Highly Selective Kinase Inhibitor, in". 2 June 2010.
  5. ↑ Jim Kling (1 April 2011). "ACT Biotech Inc". Medtech Insight. Retrieved 22 February 2023.
  6. ↑ "biotickr". biotickr. Retrieved 2022-10-23.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.